FAM19A4、PAX1及miRNA124-2基因启动子区甲基化在宫颈病变早期诊断中的价值

李雅, 刘慧, 任静静, 李肖甫, 智艳芳

  1. 郑州大学第三附属医院输血科，河南 郑州 450052
  • 收稿日期:2024-01-16 修回日期:2024-04-16 出版日期:2024-08-30 发布日期:2024-09-10
  • 通信作者: 智艳芳
  • 作者简介:李 雅（ORID：0009-0007-0917-0291），硕士研究生，主管检验师。
  • 基金资助:
    河南省医学科技攻关计划省部共建重大项目(SBGJ202101020);河南省医学科技攻关计划（联合共建）项目(LHGJ20190392)

PDF

摘要/Abstract

摘要：

背景与目的：目前有关宫颈病变的DNA甲基化研究较多，但DNA甲基化作为宫颈病变的诊断及分流指标在临床实践中的报道较少。本研究拟探讨FAM19A4、PAX1及miRNA124-2基因启动子区甲基化在宫颈病变进展中早期诊断的价值。方法：收集2020年3月—2022年3月在郑州大学第三附属医院同时行宫颈液基细胞学（thinprep cytologic test，TCT）和HPV检测的患者的宫颈细胞学标本共129例，采用甲基化特异性PCR（methylation-specific PCR，MSP）检测不同宫颈病变中FAM19A4、PAX1及miRNA124-2基因启动子区甲基化改变情况，采用受试者工作特征（receiver operating characteristic，ROC）曲线评估3个基因甲基化改变对宫颈病变的诊断价值。本研究经郑州大学第三附属医院伦理委员会批准（伦理审批编号：2023-135-01）。 结果：根据病理学检查结果分为4组：未见上皮内病变或恶性细胞（no intraepithelial lesions or malignant lesions，NILM）组（42例）、低度鳞状上皮内病变（low grade squamous intraepithelial lesion，LSIL）组（28例）、高度鳞状上皮内病变（high grade squamous intraepithelial lesion，HSIL）组（36例）和鳞癌（squamous cervical cancer，SCC）组（23例）。随宫颈病变级别的增加，FAM19A4、PAX1及miRNA124-2基因甲基化检出率逐步增高，差异有统计学意义（P均<0.05）。在HSIL组FAM19A4、PAX1、miRNA124-2甲基化检出率分别为81.2%、80.5%和71.8%，在SCC组3种基因甲基化检出率均高达100.0%；细胞学诊断宫颈癌的ROC曲线下面积（area under curve，AUC）为0.731，诊断灵敏度和特异度分别为65.9%和80.4%； FAM19A4、PAX1及miRNA124-2基因单独诊断HSIL+（HSIL和SCC）时，PAX1甲基化诊断HSIL+的效能最高，AUC为0.925，灵敏度为92.8%，特异度为87.3%；两两联合诊断时，FAM19A4与PAX1联合诊断HSIL+的AUC为0.930，灵敏度为95.7%，特异度为87.1%；FAM19A4与miRNA124-2联合诊断HSIL+，AUC为0.895，灵敏度为97.6%，特异度为85.7%；PAX1联合miRNA124-2诊断HSIL+，AUC为0.928，灵敏度为95.7%，特异度为89.1%；PAX1、FAM19A4及miRNA124-2基因甲基化联合诊断HSIL+，AUC为0.928，灵敏度为100.0%，特异度为81.8%。结论：FAM19A4、PAX1及miRNA124-2基因启动子区甲基化诊断宫颈病变具有较高的灵敏度和特异度，有潜力成为宫颈病变早期诊断的新指标。

关键词: FAM19A4, PAX1, miRNA124-2, 甲基化, 宫颈病变

Abstract:

Background and purpose: At present, there have been many reports on the study of methylation in cervical lesions, however it is still not clinically practical as a diagnostic and shunting index of cervical lesions. In this study, we intended to investigate the early diagnostic value of FAM19A4, PAX1 and miRNA124-2 methylation in promoter region in the progression of cervical lesions. Methods: A total of 129 liquid-based cytology specimens of different grades of cervical lesions diagnosed in the Third Affiliated Hospital of Zhengzhou University from Mar. 2020 to Mar. 2022. Methylation specific PCR (MSP) was used to detect the methylation changes of FAM19A4, PAX1 and miRNA124-2 genes in different cervical lesions. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of methylation changes of the three genes in cervical lesions. This study was approved by the Ethics Committee of the Third Affiliated Hospital of Zhengzhou University (No. 2023-135-01). Results: All the specimens were collected and divided into 4 groups according to the histological results: 42 cases of no intraepithelial lesions or malignant lesions (NILM), 28 cases of low grade squamous intraepithelial lesion (LSIL), 36 cases of high grade squamous intraepithelial lesion (HSIL), 23 cases of squamous cervical cancer (SCC). With the increase in the level of cervical lesions, FAM19A4, PAX1 and miRNA124-2 gene methylation detection rates increased gradually, and the differences were statistically significant (P<0.05). The methylation detection rates of FAM19A4, PAX1 and miRNA124-2 in HSIL group were 81.2%, 80.5% and 71.8%, respectively, and the methylation detection rates of three genes in SCC group were up to 100.0%. Cytological diagnosis of cervical cancer showed the area under curve (AUC) was 0.731, with a sensitivity and a specificity of 65.9% and 80.4%, respectively. When FAM19A4, PAX1 and miRNA124-2 were used alone to diagnose HSIL+ (HSIL and SCC), PAX1 methylation had the highest diagnostic efficiency, and the AUC was 0.925, with a sensitivity and a specificity of 92.8% and 87.3%. When the diagnosis was made in pairs, the AUC of FAM19A4 combined with PAX1 in the diagnosis of HSIL+ was 0.930, with a sensitivity and a specificity of 95.7% and 87.1%, respectively. The AUC of FAM19A4 combined with miRNA124-2 in the diagnosis of HSIL+ was 0.895, with a sensitivity and a specificity of 97.6% and 85.7%, respectively. The AUC of PAX1 combined with miRNA124-2 in the diagnosis of HSIL+ was 0.928, with a sensitivity and a specificity of 95.7% and 89.1%, respectively. When the PAX1 and FAM19A4 combined with miRNA124-2 in the diagnosis of HSIL+, the AUC was 0.928, with a sensitivity and a specificity of 100.0% and 81.8%, respectively. Conclusion: The methylation of the promoter regions of the FAM19A4, PAX1 and miRNA124-2 genes demonstrates high sensitivity and specificity in diagnosing cervical lesions, indicating the potential for becoming novel indicators for early diagnosis of cervical lesions.

Key words: FAM19A4, PAX1, miRNA124-2, Methylation, Cervical lesion

中图分类号: 

相关文章

[1] 陈远香, 余涛, 杨诗雨, 曾涛, 魏兰, 张彦. KDM4A通过下调BMP9促进乳腺癌细胞MDA-MB-231的迁移和侵袭[J]. 中国癌症杂志, 2024, 34(2): 176-184.
[2] 陈馨宁, 姜惠琴, 杨轶慧, 虞倩, 张春燕, 王蓓丽, 潘柏申, 郭玮. 血浆Septin9基因甲基化状态和水平在胃癌患者诊断和预后评估中的应用价值[J]. 中国癌症杂志, 2023, 33(2): 162-167.
[3] 王春桃, 葛安兴, 吴红雁, 张学艳, 杨圣, 袁红香, 程艳萍, 冯延璐, 陆欣苑, 梁戈玉. 不同级别子宫颈病变与lncRNA HOTTIP和H19单核苷酸多态性的关系研究[J]. 中国癌症杂志, 2022, 32(4): 324-334.
[4] 张晓慧 , 罗建民 , 索晓慧 , 孙国锋 , 刘洪峰 , 李　静 , 牛广旭 . SOCS1的表观遗传学修饰与急性髓系白血病的关系[J]. 中国癌症杂志, 2020, 30(8): 577-585.
[5] 王　淋 , 贾　静 , 叶星明 , 林　露 , 陈燕坪 , 陈　颖 . 直肠癌患者组蛋白甲基转移酶hSETD1A表达水平的临床预后价值[J]. 中国癌症杂志, 2020, 30(5): 369-374.
[6] 曹一鸣，朱永学. 甲状腺乳头状癌中异常甲基化基因筛查[J]. 中国癌症杂志, 2019, 29(10): 780-787.
[7] 张　雷,刘一博,刘继才,等. 评价替莫唑胺对脑胶质瘤治疗敏感性的新方法[J]. 中国癌症杂志, 2018, 28(9): 657-664.
[8] 曹一鸣,朱永学 . 甲状腺癌的DNA甲基化研究进展[J]. 中国癌症杂志, 2017, 27(4): 304-311.
[9] 邢红宇,朱明月,李 伟,等. GSTPl基因启动子甲基化与前列腺癌的相关性研究[J]. 中国癌症杂志, 2017, 27(11): 879-883.
[10] 单孟林,丁　滔,郑江花,等. 应用甲基化基因检测技术分析前列腺癌中HIC1的甲基化状态[J]. 中国癌症杂志, 2016, 26(4): 290-296.
[11] 武　丹,杨　昕,朱君玲,等. 新疆维吾尔族妇女子宫颈癌DBC1基因启动子甲基化分析[J]. 中国癌症杂志, 2016, 26(3): 208-214.
[12] 胡　强,熊　华,房静远. 大肠癌表观遗传修饰在东西方人口中的异同研究[J]. 中国癌症杂志, 2016, 26(2): 182-187.
[13] 殷复粉,王　宁,于　啸,等. 宫颈癌细胞系中HPV16 E6、E7及E6/E7基因对STK31基因甲基化状态及表达的影响[J]. 中国癌症杂志, 2015, 25(9): 641-651.
[14] 王凤,王睿,王衍晶. DNA启动子甲基化致ADAMTS9蛋白下调促进大肠癌病程进展[J]. 中国癌症杂志, 2015, 25(6): 446-451.
[15] 邓家营,赵快乐. 选择性剪接基因RBFOX1在食管鳞癌中的研究[J]. 中国癌症杂志, 2015, 25(6): 401-408.

地址：上海市东安路270号（复旦大学肿瘤医院内）　上海市抗癌协会办公室电话/传真：021-64042258

上海市通信管理局备案 　沪ICP备06014835号 　 版权所有: 上海市抗癌协会